TY - JOUR
T1 - Carbapenem-Resistant Enterobacteriaceae
AU - Iovleva, Alina
AU - Doi, Yohei
N1 - Funding Information:
Transparency Declarations: Y. Doi has served on advisory boards for Meiji, Achaogen, Allergan, Curetis, and has received research funding from The Medicines Company for a study unrelated to this work. A. Iovleva declares no conflicts of interest.
Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/6
Y1 - 2017/6
N2 - Carbapenem-resistant Enterobacteriaceae (CRE) have emerged as a major threat. Commonly used antibiotics are generally inactive against CRE. Therefore, timely detection of CRE is of paramount importance. Among CRE, those producing carbapenem-hydrolyzing β-lactamase enzymes (carbapenemase-producing Enterobacteriaceae) are particularly of concern because they tend to spread, and treatment is difficult. The carbapenemase groups most commonly encountered include KPC, NDM, and OXA-48. Treatment options are limited and include combinations of polymyxins, tigecycline, aminoglycosides, or carbapenems; newer agents with activity against CRE and better safety profiles are becoming available and will likely emerge as the preferred therapy.
AB - Carbapenem-resistant Enterobacteriaceae (CRE) have emerged as a major threat. Commonly used antibiotics are generally inactive against CRE. Therefore, timely detection of CRE is of paramount importance. Among CRE, those producing carbapenem-hydrolyzing β-lactamase enzymes (carbapenemase-producing Enterobacteriaceae) are particularly of concern because they tend to spread, and treatment is difficult. The carbapenemase groups most commonly encountered include KPC, NDM, and OXA-48. Treatment options are limited and include combinations of polymyxins, tigecycline, aminoglycosides, or carbapenems; newer agents with activity against CRE and better safety profiles are becoming available and will likely emerge as the preferred therapy.
UR - http://www.scopus.com/inward/record.url?scp=85014749179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014749179&partnerID=8YFLogxK
U2 - 10.1016/j.cll.2017.01.005
DO - 10.1016/j.cll.2017.01.005
M3 - Review article
C2 - 28457352
AN - SCOPUS:85014749179
SN - 0272-2712
VL - 37
SP - 303
EP - 315
JO - Clinics in Laboratory Medicine
JF - Clinics in Laboratory Medicine
IS - 2
ER -